vs
Side-by-side financial comparison of CHIMERA INVESTMENT CORP (CIM) and NATURES SUNSHINE PRODUCTS INC (NATR). Click either name above to swap in a different company.
NATURES SUNSHINE PRODUCTS INC is the larger business by last-quarter revenue ($123.8M vs $66.2M, roughly 1.9× CHIMERA INVESTMENT CORP). CHIMERA INVESTMENT CORP runs the higher net margin — 42.8% vs 3.3%, a 39.5% gap on every dollar of revenue. On growth, NATURES SUNSHINE PRODUCTS INC posted the faster year-over-year revenue change (4.7% vs 0.5%). Over the past eight quarters, NATURES SUNSHINE PRODUCTS INC's revenue compounded faster (5.6% CAGR vs 0.8%).
Chimera Investment Corp is a US-based real estate investment trust (REIT) primarily investing in residential mortgage-backed securities, residential and commercial mortgage loans, and other real estate-related financial assets. It delivers sustainable risk-adjusted returns for shareholders via regular dividend distributions from its investment portfolio.
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
CIM vs NATR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $66.2M | $123.8M |
| Net Profit | $28.3M | $4.1M |
| Gross Margin | — | 72.5% |
| Operating Margin | 42.6% | 4.3% |
| Net Margin | 42.8% | 3.3% |
| Revenue YoY | 0.5% | 4.7% |
| Net Profit YoY | 119.3% | 1379.4% |
| EPS (diluted) | $0.05 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $66.2M | $123.8M | ||
| Q3 25 | $65.0M | $128.3M | ||
| Q2 25 | $66.0M | $114.8M | ||
| Q1 25 | $69.2M | $113.2M | ||
| Q4 24 | $65.8M | $118.2M | ||
| Q3 24 | $66.5M | $114.6M | ||
| Q2 24 | $67.3M | $110.6M | ||
| Q1 24 | $65.1M | $111.0M |
| Q4 25 | $28.3M | $4.1M | ||
| Q3 25 | $-580.0K | $5.3M | ||
| Q2 25 | $35.5M | $5.3M | ||
| Q1 25 | $167.3M | $4.7M | ||
| Q4 24 | $-146.5M | $-321.0K | ||
| Q3 24 | $136.5M | $4.3M | ||
| Q2 24 | $56.7M | $1.3M | ||
| Q1 24 | $129.5M | $2.3M |
| Q4 25 | — | 72.5% | ||
| Q3 25 | — | 73.3% | ||
| Q2 25 | — | 71.7% | ||
| Q1 25 | — | 72.1% | ||
| Q4 24 | — | 72.0% | ||
| Q3 24 | — | 71.3% | ||
| Q2 24 | — | 71.4% | ||
| Q1 24 | — | 71.2% |
| Q4 25 | 42.6% | 4.3% | ||
| Q3 25 | -0.5% | 7.0% | ||
| Q2 25 | 54.3% | 3.7% | ||
| Q1 25 | — | 5.4% | ||
| Q4 24 | -222.6% | 3.8% | ||
| Q3 24 | — | 4.6% | ||
| Q2 24 | 84.2% | 5.1% | ||
| Q1 24 | — | 4.2% |
| Q4 25 | 42.8% | 3.3% | ||
| Q3 25 | -0.9% | 4.2% | ||
| Q2 25 | 53.7% | 4.6% | ||
| Q1 25 | 241.7% | 4.2% | ||
| Q4 24 | -222.6% | -0.3% | ||
| Q3 24 | 205.4% | 3.8% | ||
| Q2 24 | 84.2% | 1.2% | ||
| Q1 24 | 198.8% | 2.1% |
| Q4 25 | $0.05 | $0.23 | ||
| Q3 25 | $-0.27 | $0.30 | ||
| Q2 25 | $0.17 | $0.28 | ||
| Q1 25 | $1.77 | $0.25 | ||
| Q4 24 | $-2.06 | $-0.02 | ||
| Q3 24 | $1.39 | $0.23 | ||
| Q2 24 | $0.41 | $0.07 | ||
| Q1 24 | $1.36 | $0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $278.6M | $93.9M |
| Total DebtLower is stronger | $251.5M | — |
| Stockholders' EquityBook value | $2.6B | $161.6M |
| Total Assets | $15.8B | $261.1M |
| Debt / EquityLower = less leverage | 0.10× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $278.6M | $93.9M | ||
| Q3 25 | $491.5M | $95.6M | ||
| Q2 25 | $250.2M | $81.3M | ||
| Q1 25 | $253.3M | $86.5M | ||
| Q4 24 | $84.0M | $84.7M | ||
| Q3 24 | $97.3M | $78.7M | ||
| Q2 24 | $162.3M | $68.7M | ||
| Q1 24 | $169.0M | $77.8M |
| Q4 25 | $251.5M | — | ||
| Q3 25 | $251.0M | — | ||
| Q2 25 | $135.2M | — | ||
| Q1 25 | $134.9M | — | ||
| Q4 24 | $134.6M | — | ||
| Q3 24 | $134.4M | — | ||
| Q2 24 | $62.4M | — | ||
| Q1 24 | — | $2.1M |
| Q4 25 | $2.6B | $161.6M | ||
| Q3 25 | $2.6B | $166.7M | ||
| Q2 25 | $2.6B | $163.7M | ||
| Q1 25 | $2.6B | $167.1M | ||
| Q4 24 | $2.5B | $161.0M | ||
| Q3 24 | $2.7B | $162.6M | ||
| Q2 24 | $2.6B | $156.4M | ||
| Q1 24 | $2.6B | $159.7M |
| Q4 25 | $15.8B | $261.1M | ||
| Q3 25 | $15.1B | $264.8M | ||
| Q2 25 | $14.9B | $254.9M | ||
| Q1 25 | $13.2B | $252.7M | ||
| Q4 24 | $13.1B | $240.9M | ||
| Q3 24 | $13.7B | $245.3M | ||
| Q2 24 | $13.1B | $235.8M | ||
| Q1 24 | $12.5B | $247.3M |
| Q4 25 | 0.10× | — | ||
| Q3 25 | 0.10× | — | ||
| Q2 25 | 0.05× | — | ||
| Q1 25 | 0.05× | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | 0.05× | — | ||
| Q2 24 | 0.02× | — | ||
| Q1 24 | — | 0.01× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-248.9M | $9.9M |
| Free Cash FlowOCF − Capex | — | $7.6M |
| FCF MarginFCF / Revenue | — | 6.1% |
| Capex IntensityCapex / Revenue | — | 1.9% |
| Cash ConversionOCF / Net Profit | -8.78× | 2.41× |
| TTM Free Cash FlowTrailing 4 quarters | — | $28.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-248.9M | $9.9M | ||
| Q3 25 | $-137.5M | $18.5M | ||
| Q2 25 | $-7.4M | $4.3M | ||
| Q1 25 | $48.8M | $2.6M | ||
| Q4 24 | $205.7M | $12.2M | ||
| Q3 24 | $41.4M | $9.6M | ||
| Q2 24 | $69.0M | $1.3M | ||
| Q1 24 | $57.3M | $2.2M |
| Q4 25 | — | $7.6M | ||
| Q3 25 | — | $16.8M | ||
| Q2 25 | — | $3.0M | ||
| Q1 25 | — | $1.5M | ||
| Q4 24 | — | $10.0M | ||
| Q3 24 | — | $7.9M | ||
| Q2 24 | — | $-2.0M | ||
| Q1 24 | — | $-1.5M |
| Q4 25 | — | 6.1% | ||
| Q3 25 | — | 13.1% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 8.5% | ||
| Q3 24 | — | 6.9% | ||
| Q2 24 | — | -1.9% | ||
| Q1 24 | — | -1.4% |
| Q4 25 | — | 1.9% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | 3.0% | ||
| Q1 24 | — | 3.3% |
| Q4 25 | -8.78× | 2.41× | ||
| Q3 25 | — | 3.46× | ||
| Q2 25 | -0.21× | 0.81× | ||
| Q1 25 | 0.29× | 0.55× | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.30× | 2.21× | ||
| Q2 24 | 1.22× | 0.97× | ||
| Q1 24 | 0.44× | 0.94× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CIM
Segment breakdown not available.
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
